FBI NGI November 2019 Fact Sheet Statistics:

• The FBI Next Generation Identification (NGI) database contains the fingerprints of over 145.9 million individuals (both civil and criminal).
• Over 97.5% of the Tenprint Rapsheet Request (TPRS) responses were completed within 19 seconds.

Fiscal Year 2019 Average

In Touch 

with

 Your World

FREEDOM TO TRAVEL ABROAD

For the Pharma Technology Industry

FBI fingerprint-based background checks are increasingly required for U.S. Citizens to live, work and travel overseas in many countries such as China, South Korea, Australia, South Africa, Spain and Israel.

Accurate Biometrics was the first authorized FBI Channeler, to provide access to FBI Identity History Summary Checks (IdHS), or Departmental Orders (556-73). For 20 years we have been a leader in the fingerprint industry with our technology capabilities, expertise and dedicated service to government agencies and private industries.

Our expertise will assist your company:

  • National U.S. Collection Network, over 800 locations in 50 states
  • Fast access to Identity History Summary Checks for Visa  requirements direct from the FBI CJIS, several delivery options are available including a secure watermarked hard copy of the results
  • SAME DAY International fingerprint card processing
  • Certified AWS GOV Cloud Hosting Environment for FBI Channeling

For more information, contact...

Will Peterson 
Director of Business Development
708-887-9258
wpeterson@accuratebiometrics.com
AccurateBiometrics.com

Go to article: Home | The path of yeast resistanceGo to article: NSFGo to article: EditorialGo to article: ContentsGo to article: NewsGo to article: Emirates SkyCargoGo to article: The pharma industry briefingGo to article: A resolution for the new decade: resolve the US opioid crisisGo to article: Eurofins CDMOGo to article: Precision medicine: what barriers remain?Go to article: Can recyclable packaging turn the pharma industry green?Go to article: Phoenix Company InsightGo to article: PhoenixGo to article: Vertex’s Trikafta: treating the genetic basis of cystic fibrosis Go to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Q&A: talking innovation with the Association for the Cannabinoid IndustryGo to article: Yeast of burden: how to develop better antifungal drugsGo to article: Loose lips bring risks: protecting pharma against leaks and fraud Go to article: Why are patients struggling to access life-saving immune globulin?Go to article: MimotopesGo to article: Deals in brief powered by GlobalDataGo to article: Nolato Company Insight Go to article: NolatoGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue